cytometry data to rapidly identify and automate interpretation of novel cellular biomarkers. This breakthrough approach enables clients to make critical decisions in their efforts to develop and deliver safer, more precisely targeted therapies for patients. CLOUD CYTOMICS™ is broadly applicable across therapeutic areas and disease states and used throughout all stages of drug development. CytoVas is currently working with partners to exploit the technology’s potential in Cardiovascular Disease, Type 2 Diabetes, Preeclampsia, Alzheimer’s, Acute Myeloid Leukemia, Psoriasis, Rheumatoid Arthritis, and Peripheral Arterial Disease. Future studies are planned in Traumatic Brain Injury. Founded by world-renowned experts in computational biology, flow cytometry and cardiology at the University of Pennsylvania, the Company is led today by an experienced management team and scientific advisory board with a track record of success. Privately held, CytoVas is well funded by primary investments from the American Heart Association, the National Institutes of Health and the University of Pennsylvania, and a partnership with Becton Dickinson Biosciences, a world leader in flow cytometry.